Organisation paid for research Program year 2021 Source: CMS Open Payments

Aoic, LLC

Neither a doctor nor a teaching hospital

Research payments

$98,985

297 payments

Through program year 2021, Aoic, LLC is reported as receiving $98,985 in research payments, across 297 payments.

By program year

3 rows

Year	Kind	Amount	Payments
2021	Research	$24,537	67
2020	Research	$32,355	107
2019	Research	$42,094	123

Breakdown

Who paid Research payments · program years 2019–2021

Radius Health, Inc. $98,985 297 payments

Studies the money was for Research payments · program years 2019–2021

Early Effects of Abaloparatide on Bone Formation and Resorption Indices in Postmenopausal Women with Osteoporosis $7,320 16 payments
TBD Forearm Bone Mineral Density and Fracture Incidence in Postmenopausal Women with Osteoporosis Results from the ACTIVExtend Phase 3 Trial $6,704 10 payments
Cardiovascular Safety of Abaloparatide in Postmenopausal Women with Osteoporosis: Analysis from the ACTIVE Phase 3 Trial $6,287 15 payments
Effects of Abaloparatide in Women Aged 80 Years or Older with Osteoporosis Post Hoc Analysis of the ACTIVExtend Trial $5,075 8 payments
Osteoporotic Fracture Trends in a Population of US Managed Care Enrollees from 2007-2017 $4,209 8 payments
Characterizing Patients Initiating Abaloparatide, Teriparatide, or Denosumab in a Real-World Setting A US Linked Claims and EMR Database Analysis $4,034 10 payments
Unmet Needs in Osteoporosis: Primary Care Perspectives from a National Advisory Board $3,958 10 payments
Phase 1b Evaluation of the Pharmacokinetics and Pharmacodynamics of Abaloparatide Solid Microstructured Transdermal System (Abaloparatide-sMTS) in Postmenopausal Women with Low Bone Mineral Density $3,177 4 payments
An Evaluation of Treatment Patterns and Outcomes Following a Fragility Fracture in Real-world Setting $3,168 4 payments
Cardiovascular Safety of Abaloparatide in Postmenopausal Women with Osteoporosis Analysis from the ACTIVE Phase 3 Trial $3,163 3 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.